SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 593.10 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 95.23 |
| Book Value / Share | 2.27 |
| Price / Book | n/a |
| NCAV ($M) | 81.11 |
| NCAV / Share | 1.93 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.72 |
| Return on Assets (ROA) | -0.54 |
| Return on Equity (ROE) | -0.66 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.02 |
| Current Ratio | 4.02 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 111.49 |
| Assets | 125.61 |
| Liabilities | 30.38 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Pivotal bioVenture Partners Fund I, L.P. | 4.90 | -15.85 | |
| 13G/A | Novartis Bioventures Ltd | 4.70 | -21.32 | |
| 13G | LSP 7 Cooperative UA | 14.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,313 | 36,324 | 3.61 | |
| 1,185 | 41,805 | 2.83 | |
| 4,812 | 43,771 | 10.99 | |
| 1,101 | 43,334 | 2.54 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NKGN – NKGen Biotech, Inc. | NRIX – Nurix Therapeutics, Inc. |
| NTLA – Intellia Therapeutics, Inc. | OCUL – Ocular Therapeutix, Inc. |
| OMER – Omeros Corporation |
Financial data and stock pages provided by
Fintel.io